Eli Lilly and Company $LLY Shares Bought by Balentine LLC

Balentine LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 150.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,042 shares of the company’s stock after acquiring an additional 2,426 shares during the quarter. Balentine LLC’s holdings in Eli Lilly and Company were worth $3,084,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Laurel Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Norges Bank bought a new stake in Eli Lilly and Company during the second quarter valued at $8,827,714,000. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Franklin Resources Inc. lifted its position in shares of Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after buying an additional 564,736 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in shares of Eli Lilly and Company by 87.2% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock worth $898,238,000 after buying an additional 536,679 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly announced a roughly $1 billion AI investment aimed at accelerating drug discovery and strengthening its pipeline beyond GLP‑1 drugs; analysts and retail investors view this as a structural growth lever that supports longer‑term revenue diversification and investor enthusiasm following the Q4 beat. Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery
• Positive Sentiment: Topline results from the Phase 3 LIBRETTO‑432 trial show Retevmo (selpercatinib) delivered a highly statistically significant and clinically meaningful improvement in event‑free survival as adjuvant therapy in early‑stage RET fusion‑positive NSCLC — a clear clinical win that expands Lilly’s oncology franchise and increases future revenue/pipeline value. Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit
• Positive Sentiment: Lilly has built about $1.5 billion of inventory of a weight‑loss pill ahead of a planned global launch this summer, signaling commercial readiness and management’s expectation of strong demand that could accelerate near‑term revenue growth. Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill
• Positive Sentiment: Coverage highlights Lilly’s strategic moves beyond GLP‑1s — including RNA cancer programs, AI‑enabled discovery and obesity R&D — which reduce single‑product risk and support a multi‑pillar growth narrative. Eli Lilly Expands Beyond GLP-1 With RNA Cancer AI And Obesity Bets
• Neutral Sentiment: Lilly will participate in TD Cowen’s Health Care Conference on March 2 (CFO Lucas Montarce to speak); investors will watch for management commentary and any updated guidance or details on commercialization plans. Lilly to participate in TD Cowen’s 46th Annual Health Care Conference

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Truist Financial set a $1,281.00 price target on Eli Lilly and Company in a report on Thursday, February 5th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Finally, Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research note on Tuesday, December 2nd. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,218.88.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,040.12 on Tuesday. The firm has a market capitalization of $981.21 billion, a P/E ratio of 45.32, a PEG ratio of 1.21 and a beta of 0.39. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The business has a 50-day moving average of $1,053.28 and a 200-day moving average of $910.46. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter last year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 30.15%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.